J. Heijns

发表

Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

H. Putter, H. Pijl, M. Pepels, 2019, Breast Cancer Research.

Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy

S. Sleijfer, J. Foekens, A. Sieuwerts, 2014, Molecular Cancer Therapeutics.

Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)

H. Pijl, H. Guchelaar, S. Böhringer, 2016, Breast Cancer Research.

The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry

L. Kooreman, M. Pepels, V. Tjan-Heijnen, 2022, Breast Cancer Research and Treatment.

Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry

M. Pepels, M. de Boer, V. Tjan-Heijnen, 2021, Breast Cancer Research and Treatment.

A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy‐free approach in HER2‐positive metastatic breast cancer: The HAT study (BOOG 2008‐2003), a Dutch Breast Cancer Research Group trial

S. Sleijfer, A. Jager, S. Linn, 2016, Cancer.

Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment

P. de Bruijn, W. Loos, T. van Gelder, 2008, Cancer Chemotherapy and Pharmacology.

Improved circulating tumor cell detection by a combined EpCAM and MCAM CellSearch enrichment approach in breast cancer patients undergoing neoadjuvant chemotherapy detection using

S. Sleijfer, J. Foekens, J. Nortier, 2014 .

Quantification of ribociclib in dried blood spots by LC-MS/MS: Method development and clinical validation.

R. Mathijssen, P. de Bruijn, M. Lam, 2021, Journal of pharmaceutical and biomedical analysis.

Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial

H. Pijl, H. Gelderblom, V. Longo, 2020, Breast Cancer Research and Treatment.

Development of a Clinical Prediction Model for 1-Year Mortality in Patients With Advanced Cancer

D. Nieboer, A. van der Heide, J. Aerts, 2022, JAMA network open.

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

M. Welters, J. Nortier, V. Longo, 2020, Nature Communications.

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

M. Welters, J. Nortier, V. Longo, 2020, Nature Communications.

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Sung-Bae Kim, M. Buyse, M. Gnant, 2017, The Lancet. Oncology.

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial

A. Jager, F. Erdkamp, A. Haringhuizen, 2018, BMC Cancer.

Impact on Quality of Documentation and Workload of the Introduction of a National Information Standard for Tumor Board Reporting

J. Verloop, M. Hendriks, Melle Sieswerda, 2020, JCO clinical cancer informatics.

Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).

H. Putter, J. Nortier, J. Kroep, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A combined EpCAM and MCAM circulating tumor cell (CTC) CellSearch enrichment to improve CTC capture rate in stage II/III breast cancer: A Dutch Breast Cancer Trialists' Group (BOOG) side study.

S. Sleijfer, J. Foekens, A. Sieuwerts, 2013 .

Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I–IIIB breast cancer receiving chemotherapy

D. Sommeijer, E. Kampman, A. Haringhuizen, 2018, Breast Cancer Research and Treatment.

Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer

S. Sleijfer, E. Voest, A. May, 2020, ESMO Open.

Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry

M. Pepels, V. Tjan-Heijnen, F. Erdkamp, 2023, The Lancet regional health. Europe.

Clinical impact of breast MRI with regard to axillary reverse mapping in clinically node positive breast cancer patients following neo-adjuvant chemotherapy.

M. A. Beek, H. Rutten, A. Voogd, 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

H. Putter, H. Pijl, M. Pepels, 2019, Breast Cancer Research.

Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study

M. A. Beek, J. Wijsman, E. Tetteroo, 2020, Breast Cancer Research and Treatment.

Abstract P1-15-20: DIetary REstriction as an adjunct to neoadjuvant ChemoTherapy for HER2-negative breast cancer: Final results from the DIRECT trial (BOOG 2013-04)

H. Putter, M. Welters, J. Nortier, 2019, Poster Session Abstracts.

Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry

M. Pepels, V. Tjan-Heijnen, F. Erdkamp, 2023, Breast Cancer Research and Treatment.

Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival

S. Sleijfer, M. Smid, A. Jager, 2023, NPJ breast cancer.

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial

A. Jager, F. Erdkamp, A. Haringhuizen, 2018, BMC Cancer.

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.

M. Agterof, M. V. Vrancken Peeters, I. Mandjes, 2024, The Lancet. Oncology.

Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry

M. Pepels, M. de Boer, V. Tjan-Heijnen, 2024, Breast cancer research and treatment.